Subscribe

Study Summaries

LMS-04: Doxorubicin alone versus doxorubicin with trabectedin for metastatic or unresectable leiomyosarcoma

The combination of doxorubicin and trabectedin significantly improves progression-free survival compared to doxorubicin alone for the first-line treatment of metastatic or unresectable leiomyosarcoma, with an acceptable safety profile despite increased toxicity.

GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

PORTEC-3: Adjuvant Chemoradiotherapy vs. Radiotherapy Alone for High-Risk Endometrial Cancer (Final Results)

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol

CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol

NRG-GY012: Olaparib, Cediranib, and Olaparib+Cediranib vs. Cediranib in Recurrent Endometrial Cancer

NRG-GY012

DESKTOP Trial - Secondary Debulking Surgery

Secondary debulking surgery in recurrent ovarian cancer

PORTEC 2: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk

Vaginal Brachytherapy vs. Pelvic External Beam Radiotherapy in Endometrial Cancer (PORTEC-2)

RUBY: Dostarlimab plus Chemotherapy for Primary Advanced or Recurrent Endometrial Cancer

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

NRG GY018: Pembrolizumab in Advanced Endometrial Cancer

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

MITO-7: Weekly chemotherapy in ovarian cancer

Weekly chemotherapy vs. q3 weekly chemotherapy in advanced ovarian cancer